

## DAFTAR PUSTAKA

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497–506.
2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses—a statement of the Coronavirus Study Group. 2020; Available from: <https://doi.org/10.1101/2020.02.07.937862>.
3. Coronavirus disease (COVID-19) situation reports. World Health Organization. Centers for Disease Control and Prevention (CDC); 2021.
4. Situation reports. World Health Organization Indonesia. 2022.
5. Data pantauan COVID-19. Provinsi Sumatera Barat . 2022.
6. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: A multicenter study of clinical features. *Am J Respir Crit Care Med*. 2020;201(11):1380–8.
7. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Vol. 19, *Nature Reviews Microbiology*. Nat Res; 2021. p. 141–54.
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *The Lancet*. 2020 Mar 28;395(10229):1054–62.
9. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. *Diabetes Care*. 2020;43(7):1399–407.
10. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. *Sci Rep*. 2020;10(1).
11. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Vol. 109, *Clin Res Cardiol*. Springer; 2020. p. 531–8.
12. Hussain A. Diabetes in asia: special challenges and solutions. *J Diabetol*. 2018;9(3):70.
13. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. PB Perkeni; 2019.
14. Rhys W, Colagiuri S. *IDF diabetes atlas*. Diabetes Res Clin Pract. 2019;9th Ed.

15. Laporan nasional Riskesdas 2018. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB); 2019.
16. Riskesdas. Laporan Provinsi Sumatera Barat Riskesdas 2018. 2018.
17. Ye C, Zhang S, Zhang X, Cai H, Gu J, Lian J, et al. Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China. *J Med Virol.* 2020 Nov 1;92(11):2821–9.
18. Aziza L, Aqmarina A, Ihsan M, editors. Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19). Kementerian Kesehatan RI ; 2020.
19. el Zowalaty ME, Järhult JD. From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach. *One Health.* 2020;9.
20. Diagnosis and classification of diabetes mellitus. Vol. 32, *Diabetes Care.* 2019.
21. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19). 2020.
22. Yuniarti E, Indika PM, Dewata I, Barlian E. Komorbidity Mapping of COVID-19 events in West Sumatera. Vol. 4, *Geography and Geography Education.* Online; 2020.
23. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Vol. 323, *JAMA - Journal of the American Medical Association.* American Medical Association; 2020. p. 1775–6.
24. Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *J Infect Dev Ctries.* 2021 May 1;15(5):646–52.
25. Phan MVT, Ngo Tri T, Hong Anh P, Baker S, Kellam P, Cotten M. Identification and characterization of coronaviridae genomes from Vietnamese bats and rats based on conserved protein domains. *Virus Evol.* 2018;4(2).
26. Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. *Gene Rep.* 2020;19.
27. Pillay TS, Pillay TS. Gene of the month: The 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. *J Clin Pathol.* 2020;73(7):366–9.
28. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Vol. 508, *Clin Chim Acta.* Elsevier B.V.; 2020. p. 254–66.
29. Mezil SA, Mezil SA, Ahmed B. Complication of diabetes mellitus. Vol. 25. 2021.
30. Hindson J. COVID-19: faecal-oral transmission? Vol. 17, *Nat Rev.* 2020. p. 259.

31. Wilson N, Corbett S, Tovey E. Airborne transmission of COVID-19. Vol. 370, The BMJ. BMJ Publishing Group; 2020.
32. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief. 2020.
33. Rashedi J, Poor BM, Asgharzadeh V, Pourostadi M, Kafil HS, Vegari A, et al. Risk factors for COVID-19. 2020.
34. Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19 patients. *Diabetes Res Clin Pract.* 2020;166.
35. Susilo A, Martin Rumende C, Pitoyo CW, Djoko Santoso W, Yulianti M, Sinto R, et al. Coronavirus disease 2019: Tinjauan literatur terkini. Vol. 7, *J penyakit dalam Indones.* 2020.
36. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Vol. 35, *Physiology.* American Physiological Society; 2020. p. 288–301.
37. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab.* 2020;318:736–41.
38. Korsman SN. *Virology.* Churchill Livingstone Elsevier. 2020;1.
39. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. *Pedoman tatalaksana COVID-19 edisi 4.* 2022.
40. Koh J, Shah SU, Chua PEY, Gui H, Pang J. Epidemiological and Clinical Characteristics of cases during the early phase of COVID-19 pandemic: A systematic review and meta-analysis. *Front Med (Lausanne).* 2020;7.
41. Eko K. Info COVID-19 sumbar. portal resmi provinsi Sumatera Barat. 2021.
42. Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz R, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. Vol. 9, *J Clin Med.* MDPI; 2020. p. 1–22.
43. Infodatin tetap produktif, cegah, dan atasi diabetes melitus. Pusat Data dan Informasi Kementerian Kesehatan. Kemenkes; 2020. p. 1–10.
44. Living guidance for clinical management of COVID-19. World Health Organization. 2021.
45. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Vol. 17, *Nat Rev Endocrinol.* Nat Res; 2021. p. 11–30.
46. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Vol. 162, *Diabetes Res Clin Prac.* Elsevier Ireland Ltd; 2020.

47. Kategori Usia Menurut Depkes RI.
48. Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. Vol. 84, J Chin Med Assoc. Wolters Kluwer Health; 2021. p. 3–8.
49. Konsensus penatalaksanaan hipertensi 2019. Indonesia Society of Hypertension. Jakarta; 2019.
50. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/4801/2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Gagal Jantung. 2021.
51. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/642/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Ginjal Tahap Akhir. 2017.
52. Agustiyah L, Ronoatmodjo S. Karakteristik pasien terkonfirmasi COVID-19 di RSUD Al-Mulk kota Sukabumi periode september 2020-juni 2021. NersMid Jurnal Keperawatan dan Kebidanan. :158–69.
53. Jayawardhana IKW, Wardani IS, Warnaini C, Ajmala IE. Hubungan karakteristik pasien terhadap derajat keparahan COVID-19 pada pasien diabetes melitus di rumah sakit Universitas Mataram. Lombok Medical Journal. 2022;1(2):88–93.
54. Elemam NM, Hannawi H, Al Salmi I, Naeem K Bin, Alokaily F, Hannawi S. Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates. Saudi Med J. 2021;42(2):170–80.
55. Ruhama RS, Mahmudah F, Sastyarina Y. Karakteristik pasien terkonfirmasi coronavirus disease (COVID-19) di RS X Samarinda periode maret-desember 2020. Proceeding of Mulawarman Pharmaceuticals Conferences. 2021;14:262–6.
56. Zhou W, Ye S, Wang W, Li S, Hu Q. Clinical features of COVID-19 patients with diabetes and secondary hyperglycemia. J Diabetes Res. 2020;2020.
57. Shang J, Wang Q, Zhang H, Wang X, Wan J, Yan Y, et al. The relationship between diabetes mellitus and COVID-19 prognosis: A retrospective cohort study in Wuhan, China. Am J Med. 2021;134(1):e6–14.
58. Sari AR, Rahman F, Wulandari A, Pujianti N, Laily N, Anhar VY, et al. Perilaku pencegahan COVID-19 ditinjau dari karakteristik individu dan sikap masyarakat. JPPKMI Jurnal Penelitian dan Pengembangan Kesehatan Masyarakat Indonesia. 2020;1(1):32–7.
59. Putri NA, Putra AE, Mariko R. Hubungan usia, jenis kelamin dan gejala dengan kejadian COVID-19 di Sumatera Barat. Majalah Kedokteran Andalas. 2021;41(2):104–11.

60. Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. *Diabetes*. 2020;69(9):1857–63.
61. Pailungan FY, Halmar HF, Kada MKR, Rasdin, Febriana F. Gambaran gejala pada pasien COVID-19 dengan komorbid, di RSUD Labuang Baji Makassar. *Jurnal kesehatan medika udayana*. 2022;08(02):194–206.
62. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. *Clin Microbiol Infect*. 2020;26(9):1242–7.
63. Pepitasari BD, Anggraini TD. Gambaran tatalaksana terapi pada pasien COVID-19 terkonfirmasi di Rumah Sakit X Kota Surakarta periode maret-desember 2020. *IJMS*. 2021;8(2):119–26.
64. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)*. 2020;133(9):1032–8.
65. Hidayani WR. Faktor faktor risiko yang berhubungan dengan COVID 19 : literature review. *JUKMAS e-ISSN*. 2020;4(2):2715–8748.
66. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. *Front Public Health*. 2020;8.
67. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. *J Infect Public Health*. 2020;13(12):1833–9.
68. Tan CG, Rambe AYM, Haryuna SH. Hubungan antara faktor demografi dan penyakit komorbid terhadap gangguan penciuman dan pengecapan pada penderita COVID-19 yang berobat jalan di Poli Covid Rsup Haji Adam Malik Medan. *Repository USU*. 2023 20;8(2):1491–511.
69. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. *Diabetes Metab Syndr*. 2020;14(4):283–7.
70. Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19). Kementerian Kesehatan RI, Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P). 2020.
71. Yanti B, Syahputra TA, Rahma FA, Katuri RA, Safitri RM. Keanekaragaman manifestasi klinis pada coronavirus Disease 2019 (COVID-19). *Jikesi*. 2020;5(2):47–54.
72. Dong X, Cao Y yuan, Lu X xia, Zhang J jin, Du H, Yan Y qin, et al. Eleven faces of coronavirus disease 2019. *Allergy: Eur J Allergy Clin*. 2020 1;75(7):1699–709.

73. Negara INAK, Budhiresna AAG, Sari NLPEK. Hubungan antara komorbiditas dengan derajat keparahan infeksi COVID-19 di rumah sakit Sanjiwani Gianyar. *Aesculapius Medical Journal* . 2022;2(1):13–20.
74. Chávez-Reyes J, Escárcega-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR, et al. Susceptibility for some infectious diseases in patients with diabetes: The key role of glycemia. Vol. 9, *Front Public Health*. Frontiers Media S.A.; 2021.
75. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis faktor risiko kematian dengan penyakit komorbid COVID-19. *Jurnal Keperawatan Silampari*. 2020;4(1):48–55.
76. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. *Diabetes Metab Syndr*. 2020;14(5):1133–42.
77. Rifiana AJ, Suharyanto T. Hubungan diabetes melitus dan hipertensi dengan kejadian coronavirus disease-19 (COVID-19) di Wisma Atlit Jakarta Tahun 2020.
78. Amiruddin AT, Nurdin H, Arif SK, Musba AMuHT, Salahuddin A, Palinrungi AS. Hubungan penanda infeksi, penanda oksigenasi, dan faktor risiko lainnya terhadap mortalitas pasien COVID-19 dengan pneumonia saat admisi di unit perawatan intensif RSUP Dr. Wahidin Sudirohusodo. *Jurnal Anestesiologi Indonesia*. 2021;13(2):114–24.
79. Seftiya A, Kosala K. Epidemiologi karakteristik pasien COVID-19 di Kalimantan Utara. *Jurnal Sains dan Kesehatan*. 2021;3(5):645–53.
80. Khairunnisa Z, Sofia R, Magfirah S. Hubungan karakteristik dan tingkat pengetahuan dengan perilaku pencegahan COVID-19 pada masyarakat desa Paya Bujok Blang Pase kota Langsa. *Jurnal Averrous*. 2021;6(1):1–14.
81. Kurnianto E, Putra DH, Fannya P, Dewi DR. Tinjauan karakteristik pasien dengan kasus positif COVID-19 di puskesmas kecamatan Matraman. *Indonesian of Health Information Management Journal (INOHIM)*. 2021;9(2):102–8.
82. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systemic review and meta-analysis. *Aging*. 2020.
83. Alkautsar A. Hubungan penyakit komorbid dengan tingkat keparahan pasien COVID-19. *Jurnal Medika Utama* . 2021;03(01):1488–94.
84. Mudatsir M, Wulandari L, Fajar JK, Soegiarto G, Ilmawan M, Purnamasari Y, et al. Predictors of COVID-19 severity: A systematic review and meta-analysis. *F1000Res*. 2020;9(1107):1–26.
85. Di Yacovo S, Garcia-Vidal C, Viasus D, Adamuz J, Oriol I, Gili F, et al. Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus. *Medicine (United States)*. 2013;92(1):42–50.

86. Nouchi A, Chastang J, Miyara M, Lejeune J, Soares A, Ibanez G, et al. Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: A cross-sectional study. *Eur J Clin Microbiol Infect Dis*. 2021;40(4):691–7.
87. Mutiawati E, Fahriani M, Mamada SS, Fajar JK, Frediansyah A, Maliga HA, et al. Anosmia and dysgeusia in SARS-CoV-2 infection: Incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis. *F1000Res*. 2021;10(40):1–28.
88. Bayrak AF, Karaca B, Özkul Y. Could smell and taste dysfunction in COVID-19 patients be a sign of the clinical course of the disease? *The Egyptian Journal of Otolaryngology*. 2021;37(106):1–5.
89. Comoglu Ş, Öztürk S, Kant A, Arslan M, Karakoc HN, Yllmaz G. Evaluation of diarrhea in patients with COVID-19. *Dig Dis*. 2021;39(6):622–5.
90. Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). *Clinical Gastroenterology and Hepatology*. 2020;18(7):1636–7.
91. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. *Am J Gastroenterol*. 2020;115(5):766–73.
92. Yunir E, Tarigan TJE, Iswati E, Sarumpaet A, Christabel EV, Widiyanti D, et al. Characteristics of diabetic foot ulcer patients pre- and during COVID-19 pandemic: Lessons learnt from a National Referral Hospital in Indonesia. *J Prim Care Community Health*. 2022;13:1–8.
93. Tavares-Júnior JW, de Souza ACC, Borges JWP, Oliveira DN, Siqueira-Neto JI, Sobreira-Neto MA, et al. COVID-19 associated cognitive impairment: A systematic review. *Vol. 152, Cortex. Masson SpA; 2022. p. 77–97.*
94. Karmila ID. 2016. Manifestasi dermatologis pada diabetes melitus. <https://erepo.unud.ac.id/id/eprint/7636>. 2020.
95. Sakina NR. Gambaran ruam kulit pada masa pandemi COVID-19 di RSUD kota Tangerang Selatan. <https://repository.uinjkt.ac.id/dspace/handle/123456789/64305>. 2022.
96. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev*. 2020 Mar 25;36(7):1–9.
97. Tasya O. Hubungan diabetes melitus dengan tingkat keparahan pasien COVID-19 tahun 2020-2021.
98. Lestari N, Ichsan B. Diabetes melitus sebagai faktor risiko keparahan dan kematian pasien COVID-19: Meta-Analysis. *Biomedika*. 2021;13(1):83–94.